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The initiation and progression of heart failure is linked to adverse cardiac remodeling of the
extracellular matrix (ECM) during disease mainly through the deregulation of myocardial metal-
loproteinases (MMPs). Relaxin (RLX), a peptide hormone acting as a physiological cardiac effector,
is a key regulator of ECM remodeling in reproductive and nonreproductive tissues. Studying
primary cultures of mouse cardiac muscle cells and rat H9c2 cardiomyoblasts, we have obtained
evidence for a new signaling pathway activated by RLX to induce ECM remodeling that involves
the bioactive sphingolipids sphingosine-1-phosphate (S1P) and ceramide. In both cell populations,
recombinant human RLX increased sphingosine kinase activity and S1P formation, whereas sph-
ingomyelin and ceramide content were decreased in [3H]serine-labeled cells. According to the
literature, RLX promoted MMP-2 and MMP-9 expression/release. Pharmacological inhibition of
sphingolipid metabolism and silencing of sphingosine kinase 1, the enzyme responsible for S1P
formation, were able to prevent MMP expression/release elicited by the hormone and induce the
expression of tissue inhibitor of MMPs. In addition, we found that sphingolipid signaling is re-
quired for the regulation of connective tissue growth factor, a member of the CCN 1–3 family of
genes that are involved in cell proliferation and differentiation. Finally, the induction of car-
diomyoblast maturation induced by RLX was also found to be counteracted by inhibition of S1P
formation. In conclusion, these findings provide a novel mechanism by which RLX acts on cardiac
ECM remodeling and cardiac cell differentiation and offer interesting therapeutic options to
prevent heart fibrosis and to favor myocardial regeneration. (Molecular Endocrinology 29: 53–67,
2015)
Bioactive sphingolipids (SLs), mainly ceramide andsphingosine-1-phosphate (S1P), are lipid mediators
generated from the phospholipid precursor of cell mem-
branes, sphingomyelin (SM) (1), by the action of several
sphingomyelinases (SMases) (2). Ceramide can be also
formed by de novo synthesis beginning with the conden-
sation of L-serine and palmitoyl coenzyme A by serine
palmitoyltransferase. The deacylation of ceramide leads
to the formation of sphingosine (Sph), which can be phos-
phorylated by sphingosine kinase (SphK) activity to S1P
(2, 3).
The bioactive lipid S1P has been suggested to mediate
cell proliferation, differentiation and adaptation to ad-
verse conditions, thus playing a central regulatory role in
health and disease (1, 4, 5). In particular, evidence has
been provided that S1P, by binding to multiple G protein-
coupled receptors of the endothelial differentiation gene
(Edg) family, currently named S1P1–5 (1), regulates the
migration, proliferation, and survival of endothelial cells.
Moreover, S1P was reported to activate matrix metallo-
proteases (MMPs), particularly MMP-2, playing a key
role in endothelial cell migration and angiogenesis (6).
ISSN Print 0888-8809 ISSN Online 1944-9917
Printed in U.S.A.
Copyright © 2015 by the Endocrine Society
Received July 10, 2014. Accepted November 14, 2014.
First Published Online Novemebr 21, 2014
* A.F. and B.R. have contributed equally to this manuscript.
Abbreviations: Ct, cycle threshold; CTGF, connective tissue growth factor; Cx43, con-
nexin-43; DNase, deoxyribonuclease; ECM, extracellular matrix; MI, myocardial infarction;
MMP, matrix metalloprotease; MT1, membrane type 1; RLX, relaxin; RXFP1, Relaxin/
insulin-like family peptide receptor 1; SCR, scrambled; siRNA, short interfering RNA; SL,
sphingolipid; SM, sphingomyelin; SMase, sphingomyelinase; S1P, sphingosine-1-phos-
phate; SphK, sphingosine kinase; TIMP, tissue inhibitors of MMP.
O R I G I N A L R E S E A R C H







end/article/29/1/53/2556816 by guest on 08 N
ovem
ber 2020
S1P has also been shown to promote the relocalization
of membrane-associated membrane type 1 (MT1)-MMP
(MMP-14) to peripheral actin-rich membrane ruffles at
the leading edge of bone marrow-derived stromal cells
required for cell migration (7). Conversely, the other bio-
active SL, ceramide, was reported to play opposite func-
tions to S1P; for instance, in keratinocytes, ceramide in-
duces a fibrogenic phenotype, because it stimulates the
expression of TGF-, elastin, MMP-1, and MMP-9,
whereas MMP-2 was not affected (8).
MMPs are a family of more than 25 species of zinc-
dependent proteases essential for the remodeling of extra-
cellular matrix (ECM), a key event underlying a broad
variety of physiological and pathological processes (9).
MMPs are regulated at multiple levels including tran-
scription, expression, secretion, and activation from in-
active zymogens, and their activity is under the strict
control of specific inhibitors, named tissue inhibitors of
MMPs (TIMP). Aberrant expression of MMPs has been
reported in several diseases, including cancer infiltration
and metastasization, angiogenesis, inflammation, arthri-
tis, pulmonary emphysema, multiple sclerosis, chronic
wounds, and heart failure (6, 10). Among the MMPs ex-
pressed in the heart (reviewed in Ref. 11), MMP-2 and
MMP-9, which are responsible for degradation of type IV
collagen, the major component of basement membranes,
appear to play an important role in adverse myocardial
remodeling. In fact, increased gelatinases were found in
both experimental and clinical heart failure (9, 12), whereas
their deficiency in gelatinase-null mice was shown to pre-
vent cardiac rupture and attenuate left ventricular en-
largement and collagen accumulation after acute myocar-
dial infarction (MI) (9, 13).
Notably, stimulation of ECM turnover and modula-
tion of MMP expression and activity is a hallmark of the
biological effects of the hormone relaxin (RLX) (14, 15).
This is a member of the RLX peptide family which, in
humans, encompasses 3 forms of RLX (H1, H2, and H3)
and 4 insulin-like peptides (INSL-3 to -6) (16). Of these,
H2 RLX, chiefly produced by the corpus luteum, is the
main circulating hormone (16). The ECM-remodeling ef-
fects of RLX have been well documented in several organs
and are mediated by its ability to inhibit profibrotic cyto-
kine (primarily TGF-1) signal transduction and hence
the ability of these profibrotic factors to promote myofi-
broblast differentiation and subsequent myofibroblast-
mediated ECM synthesis, deposition, and accumulation
(17). Additionally, RLX stimulates a net increase in ECM
degradation by promoting the actions of various MMPs,
including MMP-1, MMP-2, and MMP-9 (17, 18), while
inhibiting TIMPs. These combined actions of the hormone
have collectively contributed to its development as a po-
tential antifibrotic agent. Recent in vitro studies using
human (19) and rodent (20) fibroblasts have demon-
strated that RLX disrupts TGF-1 activity by interfering
with its signal transduction at the level of Smad2 phos-
phorylation, as a means of inhibiting TGF-1-induced
myofibroblast differentiation, ECM production, and reg-
ulation of MMP activity.
The ability of RLX to increase ECM turnover by stim-
ulating MMP expression/secretion is crucial to its physi-
ological roles, especially in the cardiovascular system. In
fact, it has been shown to be produced by the heart (21),
to act on specific heart receptors (16), and to exert specific
effects on the cardiovascular system, including coronary
vasodilatation and neoangiogenesis (14, 22, 23).
A prominent role of RLX in cardiac diseases is also
emerging. In fact, studies in RLX-null mice have demon-
strated an age-related increase of fibrosis in the heart that
can be reversed by H2 RLX administration (14, 24). In
humans, myocardial upregulation of RLX expression has
been reported in heart failure patients and interpreted as
a compensative mechanism to sustain impaired cardiac
function (21). In keeping with these findings, a recent
phase III clinical trial on a cohort of patients with conges-
tive heart failure has offered preliminary albeit convinc-
ing evidence that iv administration of recombinant H2
RLX can improve some key parameters of cardiac func-
tion and enhance the odds of survival (25, 26).
Although the ability of RLX to increase ECM turnover
by stimulating MMPs expression/secretion is crucial to its
physiological roles, the complex mechanisms whereby the
hormone achieves these effects remain to be completely
elucidated. Moreover, no data are yet available on the
ability of RLX to regulate the expression of connective
tissue growth factor (CTGF). This is a member of the cys-
teine-rich 61/CTGF/nephroblastoma overexpressed (CCN
1–3) family of genes (CCN family), which are operating in
key biological processes such as cell proliferation, differen-
tiation, adhesion, migration, and survival (27–29).
Based on the above reported similarities between the
effects of S1P and RLX on MMP modulation, we hypoth-
esized that bioactive SLs may be involved in the response
of cardiac muscle cells to RLX.
In the present study, we provide the first evidence that
RLX can activate SphK and upregulate S1P production in
primary culture of mouse neonatal cardiac muscle cells
and in rat H9c2 cardiomyoblasts. In addition, we show
that the induction of SL metabolism and the decrease in
S1P and ceramide synthesis triggered by RLX play a
key role in the mechanisms presiding over MMPs and
CTGF expression/release as well as cardiac muscle cell
proliferation/differentiation.











Cell culture and treatment
Primary cultures of mouse ventricular cardiac muscle cells
were prepared from hearts of 1- to 2-day-old newborn Swiss
mice (Harlan) and cultured as previously described (30). Iso-
lated primary cardiac muscle cells were used for the first 2 weeks
(passages 0–1). Rat H9c2 cardiomyoblasts were from American
Type Culture Collection. Both cell populations were incubated
in serum-free essential medium overnight before treatment with
the indicated concentrations of recombinant H2-RLX (Connet-
ics Co) and/or inhibitors. PD98059, specific inhibitor of MAPK,
SB202190, a highly selective, potent, and cell-permeable inhib-
itor of p38 MAPK (Tocris Bioscience). SL metabolism enzyme
inhibitors used in the study were GW4869, a cell-permeable,
noncompetitive inhibitor of neutral SMases (31, 32) and SKI-II,
selective nonlipid inhibitor of SphK (33), were from Tocris Bio-
science. THI, inhibitor of S1P lyase (34) was obtained from
Sigma-Aldrich s.r.l.
SphK activity measurement
SphK activity was determined essentially as described previ-
ously (35, 36). Briefly, equal amounts of protein (60 g) from
primary cardiac muscle cells and H9c2 cells were incubated in
assay buffer in the presence of 20 mol/L Sph and 200 mmol/L
[32P]ATP (3 Ci/assay). SphK activity was measured in a typical
buffer solution for detecting mainly SphK1 isoform activity.
Reactions were started with the addition of lysate proteins and
incubated for 30 minutes at 37°C. The formed [32P]S1P in the
organic phase was separated by TLC on Silica Gel 60 using
CH3(CH2)3OH/ CH3COOH/H2O (3:1:1, vol:vol) (37). The ra-
dioactive spots corresponding to authentic S1P were identified
and quantified by scraping from the plates and counting the
radioactivity in a Beckman LS1000 counter.
Quantification of cellular SLs in primary cardiac
muscle cells
SLs were quantified essentially as previously described in De
Palma et al (38). Cardiac muscle cells were incubated with se-
rum-free medium and 2 Ci of [3H]serine for 24 hours. Total
lipids were extracted by the addition to cells of CHCl3: CH3OH:
HCl (100:200:1, vol:vol). The lower phase was evaporated and
lipids separated by TLC on Silica Gel 60 with CH3(CH2)3OH/
CH3COOH/H2O (3:1:1, vol:vol). The radioactive spots corre-
sponding to S1P were identified and quantified as described
above.
RT-PCR analysis
To evaluate the expression levels of mRNA for Relaxin/in-
sulin-like family peptide receptor 1 (RXFP1), RT-PCR was per-
formed using mouse cardiomyocytes and rat H9c2 cells. Mouse
and rat atria, which constitutively express RXFP1, were used as
positive controls. Total RNA was isolated by extraction with
TRIzol reagent (Invitrogen) according to the manufacturer’s in-
structions. To avoid genomic DNA contamination, the samples
were treated with 2 to 10 U deoxyribonuclease (DNase) I
(Roche Diagnostics or Invitrogen). TIMP-1 amplification using
untreated RNA and DNase-treated RNA is reported (note the
presence of a higher band corresponding to an amplified intron
region indicating the contamination by genomic DNA). One
microgram of total RNA was reverse transcribed and amplified
with the SuperScript One-Step RT-PCR System (Invitrogen).
After cDNA synthesis for 30 minutes at 55°C, the samples were
predenatured for 2 minutes at 94°C and then subjected to 38
cycles of PCR performed at 94°C for 15 seconds, alternating
with 55°C for mouse RXFP1 and 57°C for rat RXFP1 for 30
seconds and 72°C for 1 minute; the final extension step was
performed at 72°C for 5 minutes. The following specific primers
were used: mouse RXFP1 (NM_212452.1) forward 5-ACG
AGC TGT CCC ATC AGT TT-3 (354–372 bp) and reverse
5-ATG TGC TGA CAG AGG GGT TT-3 (718–737 bp) (tran-
script length 383 bp); rat RXFP1 (NM_ 201 417.1), forward
5-CGG ATG GGA TCT CCT CTC TT-3 (1178–1197 bp) and
reverse 5-GCG TGC TTC CTG TAC TCT CC-3 (1408–1427
bp) (transcript length 249 bp). Both primers were designed to
span an intron. Negative controls, consisting of no template
(water), were performed in each run. PCR products were elec-
trophoresed on a 2% agarose gel.
To evaluate the expression of S1P receptor subtypes, total
RNA from cardiomyocytes and H9c2Cells were isolated by ex-
traction with TRI Reagent (Sigma-Aldrich, s.r.l.), according to
the manufacturer’s instructions. Concentration and purity of
extracted total RNA were evaluated by measuring the absor-
bance at 260 and 280 nm wavelength and the absence of degra-
dation confirmed by agarose gel electrophoresis with ethidium bro-
mide staining.
One microgram of total RNA from H9c2 and primary car-
diac muscle cells were reverse-transcribed to single-stranded
cDNA using the commercially available cDNA Synthesis Kit
(SuperScript III cells Direct cDNA Synthesis Kits; Life Technol-
ogies) or SuperScript One-Step RT-PCR System (Invitrogen) ac-
cording to the manufacturer’s instructions. Mouse C2C12 cells,
which constitutively express S1P1, S1P2, and S1P3 were used as
positive controls. Samples were incubated at 70°C for 10 min-
utes, 25°C for 15 minutes, 42°C for 60 minutes, and then
70°C for 5 minutes in a thermal cycler (PerkinElmer). To
amplify S1P receptor subtypes, we chose forward and reverse
primers in a region of nucleotide sequences identical in rat
and mouse genes: S1P1 (NM_007901), S1P2 (NM_010333),
and S1P3 (NM_007901). Because the coding region covers a
single exon, to avoid genomic DNA contamination, the samples
were treated with 10 U DNase I (Roche Diagnostics). The prim-
ers were designed as follows: S1P1 forward 5-CCG CAA GAA
CAT CTC CAA GG-3 (711–730 bp) and reverse 5-GGC AAT
GAA GAC ACT CAG GA-3 (782–801 bp) (transcript length
91 bp); S1P2 forward 5-CAT CGT GGT GGA GAA TCT TCT
G-3 (138–159 bp), and reverse 5-CAG GTT GCC AAG GAA
CAG GTA-3 (203–225 bp) (transcript length 88 bp); and S1P3
forward 5-CCA CCT GCA GCT TAC TGG CC-3 (377–396
bp) and reverse 5-GGC AAT TAG CCA GCA CAT CCC-3
(478–498) (transcript length 122 bp). For amplification of
TIMP-1, MMP-2, and MMP-9, the primers were designed as
following: rat TIMP-1 (NM_053819.1) forward 5-GAC CAC
CTT ATA CCA GCG-3 (162–179 bp) and reverse 5-ACA
CCC CAC AGC CAG CAC TA-3 (429–448 bp) (transcript
length 287 bp, with 2 introns 674 bp); rat MMP-9 (
NM_031055.1) forward 5-TCG AAG CAG ACA TTG TCA-3
(488–505 bp) and reverse 5-TCG TCG TCG TCG AAG TGG
GC (607–626 bp) (transcript length 139 bp); and rat MMP-2
(NM_031054.2) 5-TGA CGG CAA GGA CGG ACT C-3
(552–570 bp) and reverse 5-CTT GCA GTA CTC GCC
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ATC-3 (684–701bp) (transcript length 150bp). Negative con-
trols for reverse transcription were performed using DNase-
treated RNA and for PCR consisted of no template (water).
Real-time PCR.
Quantitative real-time PCR was carried out using the
Rotor.Gene 6000 (Corbett Research, Corbett Life Science) and
Sybr Green reagents (Life Technologies) consisting of a specific
set of primers (200nM) and a fluorogenic internal probe. The
expression of S1PR genes were quantitated in comparison with
the housekeeping gene GAPDH. PCR amplifications were per-
formed on cDNA samples corresponding to a final RNA con-
centration of 50 ng. PCR was performed in a total volume of 25
L containing 2 PCR Master Mix (Life Technologies). Reac-
tion conditions were as follows: 95°C for 10 minutes, followed
by 35 to 40 cycles at 95°C for 30 seconds alternating with 52°C,
55°C. or 60°C for 30 seconds and 72°C for 45 seconds. PCR
amplifications were run in duplicates.
Blank controls were performed in each run. The results of the
real-time PCR were presented as cycle threshold (Ct) values,
where Ct was defined as the PCR threshold cycle at which am-
plified product was first detected. All values were normalized to
the GAPDH housekeeping gene expression and Ct calculated.
Cell silencing by short interfering RNA
To inhibit the expression of SphK1, a mix of short interfering
RNA (siRNA) duplexes corresponding to 2 distinct regions of
the DNA sequence of SphK1 gene (SphK1-siRNA) was used as
previously reported (35): SphK1 siRNA1 (5-GGG CAA GGC
UCU GCA GCU CdTdT-3) and SphK1-siRNA2, (5-AAG
GGC AAG CAU AUG GAA CdT dT-3). H9c2 cells (200 000
cells per well) were transfected with a mix of both SphK1-siR-
NAs (100nM) using Lipofectamine 2000 reagent according to
manufacturer’s instructions. After 36 hours from the beginning
of transfection, conditioned medium and cells were collected
and used for the reported experiments. Nonspecific scrambled
(SCR) siRNA was used as control. The specific knockdown of
SphK1 was evaluated by Western blotting, and the efficiency of
transfection was estimated as approximately 65%  8% (n  3)
Gelatin zymography
MMP/collagenase activity was assessed by gelatin zymogra-
phy from conditioned medium (30). Cells were analyzed after
24 to 48 hours in culture as indicated. In some experiments,
primary cardiac muscle cells and H9c2 cardiomyoblasts were
incubated for 30 minutes in the presence or absence of the spe-
cific compounds or inhibitors. After 24 hours, the conditioned
medium was collected and centrifuged at 10 000g for 15 min-
utes and stored at 20°C. Samples, 10 to 20 L each, were
mixed with sample buffer and separated on 10% SDS-poly-
acrylamide gels containing gelatin (1 mg/mL), and gel was de-
veloped as reported previously (30). The MMPs appear as
bright bands within the stained gel, and the clear bands indicate
proteolytic activity. MMPs were identified by comparison with
molecular weight standards.
MMP measurement by ELISA
Culture media obtained from the 24 hours of incubation of
cardiac cells were thawed and used in the MMP-2/-9 ELISA
(Boster Biological Technology Co Ltd), according to the manu-
facturer’s protocols with minor modifications. The resultant
reactions were read at a wavelength of 450 nm in a microplate
Bio-Rad reader. Three independent experiments were carried
out and duplicates of each sample were measured with the
ELISA kit. Data (means  SEM), reported as nanograms per
milliliter, were calculated by interpolating the absorbance in a
standard curve.
Western blotting analysis
To prepare total extracts, native and transfected cells were
processed as previously described (39 – 41) Proteins (30 g)
from lysates or cellular fractions were subjected to electropho-
resis (SDS-PAGE) and Western analysis as previously described
(42). To immunodetect endogenous RXFP1, rabbit polyclonal
antirelaxin receptor (RXFP; 1:3000; Immunodiagnostik) was
used. Specific polyclonal anti-SphK1 antibodies from ECM Bio-
science were used to evaluate the expression of SphK1, whereas
rabbit polyclonal antibodies against amino acids 363 to 382 of
human/rat connexin-43 (Cx43) (Sigma) were used for detecting
the state of cardiac muscle cell differentiation. Anti-CTGF an-
tibodies (PA5–32193 against amino acids115- 315 of human
CTGF) to detect CTGF/CNN2 and TIMP-1 (mouse IgG1, clone
102D1) were from Merck Millipore. Bound antibodies were
revealed by antirabbit, antimouse or antigoat IgG1 conjugated
to horseradish peroxidase (Santa Cruz Biotechnology, Inc) and
Enhanced chemiluminescence (ECL) reagents (Amersham Phar-
macia Biotech). Rabbit polyclonal anti-SphK1 antibodies were
from ECM Biosciences LLC. Anti–-actin or anti–-tubulin
(Santa Cruz) was used to demonstrate the quality and equiva-
lent loading of protein.
Cell proliferation analysis
Primary cardiac muscle cells were incubated for 24 hours
in DMEM in the absence of the indicated compounds, and
[3H]thymidine (2 Ci/mL) (PerkinElmer) was added to the me-
dium for the last hour of incubation. Cells were processed as
reported (36, 42), and the recovered radioactivity was measured
in a -counter (Beckman).
Statistical analysis
Representative zymographs or blots are reported. Densito-
metric analysis of the bands was performed using Imaging and
Analysis Software by Bio-Rad (Quantity-One) or ImageJ (Na-
tional Institutes of Health) software and reported as relative
percentage (means  SEM) obtained by calculating the ratio of
the band intensity of the specific protein to -actin or -tubulin
intensity and normalizing to control, set as 100. In zymographs,
the amount of gelatinolytic activity of the control sample was
arbitrarily set to 100% in each gel. The MMP activity of the
samples was interpolated from the standards curve, and data
from independent experiments performed in duplicates are re-
ported as relative percentage above control (means  SEM). In
ELISA tests, MMP concentration is reported as nanograms per
milliliter (means  SEM). Statistical significance for all meth-
odological approaches was determined by Student’s t test or
one-way ANOVA, with a value of P  .05 considered signifi-
cant. At least 3 independent experiments were performed for the
studies (zymographs and blots) involving primary cardiac mus-
cle cells, whereas 4 to 6 independent experiments were carried
out for the studies involving the H9c2 cells.











RLX triggered SL metabolism
SL metabolism is involved in the signaling pathways of
several hormones in many cell types (43). As in our pre-
vious studies (30, 44), we used primary cultures of mouse
neonatal cardiac muscle cells to investigate the potential
role of bioactive SLs in the typical cell responses to RLX.
Upon isolation, they appear as scattered round or poly-
hedral cells. After 24 hours incubation, the cells formed
rhythmically beating clusters (Supplemental Figure 1).
The reported analyses were performed at this stage.
We first investigated whether RLX was able to modu-
late the activity of SphK, the enzyme responsible for S1P
synthesis. Enzyme activity was measured on cell lysates
obtained from both primary murine cardiac muscle cells
and H9c2 cardiomyoblasts. As shown in Figure 1, RLX
(50 ng/mL) induced a significant increase in SphK activity
in both cell types, reaching a maximal stimulation at 15
minutes. At this time point, lower RLX doses (down to 10
ng/mL) were also efficient (data not shown). Because the
enzyme activity assay was performed in a buffer without
KCl, the [32P]S1P formed during the assay can be chiefly
attributed to the activation of SphK1 isoform (33). No-
tably, after long-term exposure (24 hours), RLX did not
substantially increase the expression of SphK1 (Figure 1,
inset), supporting the involvement of a posttranslation
modification in enzyme activation.
Because it has been reported that the content of bioactive
SLs is crucial for cell fate (1, 3, 35, 36, 38, 41), we then
explored whether RLX changed the levels of SM and its
distal metabolites, ceramide, Sph, and S1P, in primary car-
diac muscle cells labeled with [3H]serine. As shown in Figure
2, a significant increase in [3H]Sph and [3H]S1P formation
was detected 15 and 30 minutes after RLX treatment,
whereas [3H]SM and [3H]ceramide content were signifi-
cantly reduced at these time points. Notably, S1P levels in-
creased earlier than the levels of Sph, suggesting that as soon
as [3H]Sph is formed by [3H]SM degradation, the lipid is
rapidly phosphorylated to [3H]S1P by activated SphK.
The classical signaling pathways activated by RLX in
target cells, such as fibroblasts (45, 46), involve the activa-
tion of RXFP1/ERK1/2 signaling. Thus, because ERK1/2
has been reported to be crucial for SphK activation (2, 3),
first we determined the expression of RXFP1 in H9c2 and
primary cardiac muscle cells. Both cell populations express
RXFP1 at the mRNA and protein level as demonstrated by
RT-PCR analysis and Western blotting shown in Figure 3, A
and B, respectively. Positive controls corresponding to mu-
rine heart tissue (atria) are also reported in the same figure.
Successively, we established the po-
tential role of ERK1/2 and p38 MAPK
and ERK in RLX-induced enzyme ac-
tivation performing pharmacological
inhibition of ERK1/2 by PD098059
and of p38 MAPK by SB202190 (Fig-
ure 3C). Of note, the RLX-induced
activation of SphK was prevented by
PD098059 as well as by U0126 (5M),
another recently identified MAP ki-
nase kinase kinase (MEKK) inhibitor
(Figure 3D), whereas SB202190 did
not affect enzyme activity. Neither
PD098059 nor SB202190 treatment
significantly affected basal SphK
activity.
Altogether, these findings suggest
that SM-derived bioactive SLs are
novel effectors in the signaling path-
ways promoted by the RLX/ERK1/2
axis in cardiac cells.
S1P formation and de novo
synthesis of ceramide are
required for RLX-induced MMPs
Because RLX is known for its
ECM-remodeling properties (14, 30),
Figure 1. RLX induces SphK activity in primary cardiac muscle and H9c2 cells. A and B, SphK
activity was determined in cell lysates (30–50 g) obtained from untreated primary cardiac muscle
cells (A) and H9c2 cells (B) and cardiac cells treated with RLX (50 ng/mL) over the indicated time.
Results are expressed as mean  SEM of at least 3 independent experiments with analogous results
performed in duplicate (Student’s t test; *, P  .05). C, Representative Western blot of SphK1 isoform
expression in H9c2 cells. Cell lysates (25 g) were subjected to SDS-PAGE and SphK1 isoform
immunodetected by specific rabbit polyclonal antibodies. Band intensity, reported as relative
percentage of control, was arbitrarily normalized to 100 (mean of 3 experiments, SEM 15%).
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we then studied whether the bioactive SLs could be a part of
the RLX-induced signaling leading to the induction of latent
and active MMP expression/release. The conditioned me-
dium obtained from both cell cultures treated or not with
RLX was used for gelatin zymography and ELISA to iden-
tify and quantify the gelatinases released by the cells. As
shown in Figure 4, A–C, latent and active MMP-9 of 92
and 85 kDa, respectively, and active MMP-2 (72 kDa)
Figure 2. RLX treatment promotes SL metabolism. Primary cultures of cardiac muscle cells were incubated for 24 hours with [3H]serine and then
treated with or without RLX (50 ng/mL) for the indicated times. SLs were extracted as reported in Materials and Methods and 3H-radiolabeled SM
(A), ceramide (B), sphingosine (C), and S1P (D) quantified as in Materials and Methods. SL content on total radiolabeled lipids is reported as
mean  SEM of at least 3 independent experiments (Student’s t test; *, P  .05).
Figure 3. RLX receptor subtype expression and effect of ERK1/2 and p38 MAPK inhibitors on RLX-induced SphK activity. A, Representative
agarose gel. Expression of RLX receptor subtype (RXFP1) mRNA in H9c2, cardiac muscle cells, and atria. RT-PCR was performed as in Materials and
Methods from H9c2, cardiac muscle cells, and atria mRNA (2 g). B, Representative Western blotting. RXFP1 was immunodetected by specific
polyclonal antibodies in cell lysates (20 g) of H9c2 and primary cardiac muscle cells and murine tissue (atria). C and D, ERK1/2 or p38 MAPK
specific inhibitors PD98059 (15M), UO126 (5M), and SB202190 (10M) were added to the cell medium alone or 30 minutes before RLX
treatment. SphK activity was determined as described in Figure 1 and in Materials and Methods. Data are mean  SEM of at least 3 independent
experiments (Student’s t test; *, P  .05 vs vehicle; §, P  .05 vs RLX).
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Figure 4. Inhibition of S1P synthesis on RLX-induced MMP-9 and MMP-2 release in primary cardiac muscle cells and H9c2 cells. A and B, A
representative gelatin zymograph of latent (L) and active (A) MMP-9 and MMP-2 from conditioned media obtained from primary cardiac muscle
cells (A) and H9c2 cardiomyoblasts (B) treated for 30 minutes with compound II (iSK, 5M) before the addition of RLX (50 ng/mL) for another 24
hours. Densitometry scanning from at least 3 separate experiments for each cell type studied was performed, and data expressed as relative OD
values (L-MMP-9, A-MMP-9, and overall MMP-9) to those of the untreated group (vehicle) set to 100, are reported in the graphics. Data are
mean  SEM (ANOVA test; *, P  .05 vs untreated cells (vehicle); §, P  .05 vs RLX). C, A representative gelatin zymograph of MMP-9 from
conditioned media obtained from H9c2 cells transfected with 50nM scrambled (SCR-siRNA) or SphK1-specific siRNA (SphK1-siRNA) for 24 hours
and then treated or not with RLX (50 ng/mL) for another 24 hours. Samples were analyzed as reported in Materials and Methods and statistical
significance calculated as above. D, SphK activity. H9c2 cells transfected with scrambled (SCR-siRNA) or SphK1-specific siRNA (SphK1-siRNA) as in
C were used for SphK activity assay and SphK1 protein expression analysis. Inset, Proteins from H9c2 cell lysate (30 g) were separated by SDS-
PAGE and blotted, and SphK1 was immunodetected using specific polyclonal antibodies as described in Materials and Methods. Data are mean 
SEM of 3 independent experiments performed in duplicate (Student’s t test; *, P  .05). Relative percentage of SphK1 expression is indicated in
the inset (SEM 15%). E and F, Conditioned cell media from primary cardiac muscle and H9c2 cells, incubated and treated as reported above,
were analyzed by ELISA. Relative OD450nm was measured by microplate reader and sample concentration interpolated using a standard curve. Two
independent experiments in duplicate were carried out, and data are reported as percentage above control (vehicle). Data (nanograms per
milliliter) are mean  SEM (ANOVA test; *, P  .05 vs untreated cells (vehicle); §, P  .05 vs RLX).
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were detected in the supernatants from both primary car-
diac muscle cells and H9c2 cardiomyoblasts upon 24
hours of incubation. An RLX dose of 50 ng/mL was
found effective in enhancing the release of either MMP-9
or MMP-2, and in both cell populations, the effect of
RLX was prevented by incubating the cells in the presence
of SphK inhibitor (compound II, iSK) (Figure 4, A and B).
The involvement of the isoform SphK1 in RLX-induced
MMP-9 release was demonstrated by SphK1 gene silencing
in H9c2 cells. As reported in Figure 4, the transfection of
H9c2 cells with SCR-siRNA or SphK1-siRNA for 24
hours strongly inhibited the release of MMP-9 promoted
by RLX (Figure 4C) and significantly reduced SphK ac-
tivity and enzyme expression of approximately 85% and
55%, respectively (Figure 4D and inset). The enhanced
release of MMPs elicited by the cardiotropic hormone
and the role of SphK inhibition in counteracting hormone
action in cardiac cells was further confirmed by ELISA
(Figure 4, E and F).
Altogether, these data demonstrate for the first time a
correlation between the ability of RLX to promote ECM
remodeling and the activation of the SphK/S1P axis.
To further investigate the involvement of SM-derived
metabolites in the RLX-induced release of MMPs, we
evaluated by zymography and ELISA the effects of other
inhibitors of SL metabolism, namely GW4869, a non-
competitive inhibitor of neutral SMases (32), and THI, a
rather specific inhibitor of S1P lyase (34). Before perform-
ing the zymography and ELISA, we tested the dose of S1P
lyase, SMase, and SphK inhibitors. As reported in Table
1, quantification of mRNA encoding MMP-9, MMP-2,
and TIMP-1 in untreated H9c2 cells or cells treated with
the indicated concentrations of inhibitors (THI, GW, or
iSK) and S1P. Ct revealed no significant effects of the
treatment on RNA expression, indicating that the dose
used to specifically inhibit S1P lyse, SMase, and SphK
activity was not cytotoxic. The exogenous addition to the
cell medium of the bioactive lipid, S1P, was also evalu-
ated. As shown in Figure 5, A–C, zymography analysis
indicated that, similarly to iSK, GW4869 treatment and
exogenous addition of S1P led to a significant reduction
of RLX-promoted release of MMP-9 (approximately 30%
and 90%) in cardiac muscle cells as well as in H9c2 cells
(Figure 6B). On the contrary, THI treatment was ineffec-
tive on either MMP-9 or MMP-2.
The correlation between SL mediators and MMP-9
release was further proven by a sensitive ELISA (Figure 5,
C and D). Of note, the addition of exogenous S1P to cell
medium strongly reduced the effect of RLX on MMP-9
release at similar extent than iSK alone, suggesting a
role for the signaling downstream of the specific S1P
receptors (3).
In keeping with these findings, we found that the ex-
pression of TIMP-1, the endogenous inhibitor of MMPs,
was reduced approximately 45% by RLX (Figure 6A),
and the treatment with SphK inhibitor, GW4869, or ex-
ogenous S1P, before hormone addition, significantly pre-
vented its effect. On the contrary, no change was observed
when the cells were treated with THI (Figure 6B).
RLX reduced CTFG expression through SL
metabolism
CTGF (CCN2) is thought to play an important role in
cardiac remodeling (28, 29). As shown in Figure 7A, RLX
and the inhibitor of SphK significantly reduced the basal
level of CTGF in primary cardiac muscle cells. Of note,
the downregulation of CTGF elicited by RLX was further
enhanced by SphK inhibition, whereas GW4869 and S1P
treatment had no effect. On the contrary, in H9c2 cells,
the addition of iSK to the culture medium significantly
prevented hormone action, whereas the treatment with
GW4869 and the exogenous addition of S1P further po-
tentiated RLX-induced decrease of CTGF expression
(Figure 7B).
Table 1. Effect of SphK, SMase, and S1P Lyase Inhibition and S1P Addition on MMP-9, MMP-2, and TIMP-1
Expression in H9c2 Cellsa
Control iSK GW4869 THI S1P
MMP-9
Ct 29.66 24.1 24.6 24.47 25.02
Ct 7.64  0.8 6.76  0.6 6.72  0.7 5.57  0.7 7.25  0.7
MMP-2
Ct 33.09 27.7 28.47 28.05 28.09
Ct 11.07  1.0 10.38  1.2 10.59  1.0 9.15  1.2 10.32  1.1
TIMP-1
Ct 31.75 25.74 26.61 26.4 25.87
Ct 10.5  1.1 9.35  1.0 9.18  1.1 9.33  1.1 9.21  1.0
a MMP-9, MMP-2, and TIMP-1 expression was evaluated from RNA extracted from untreated H9c2 (control) cells and cells treated for 30 minutes
with compound II (iSK, 5M), GW9846 (10M), THI (6.5M), or S1P (1M). Total RNA was reverse transcribed and real-time PCR amplification
performed as described in Materials and Methods. Ct values are reported as mean  SEM for independent experiments performed in duplicate.
Significance of differences was tested by one-way ANOVA, and no significant change was observed in the presence of inhibitors vs control.
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Therefore, by comparing the effects of iSK and S1P in
primary cardiac muscle cells and H9c2 cells, we can hy-
pothesize a different role for the intracellularly formed
S1P and the signaling pathways induced by exogenous
S1P at different stages of cell maturation. Notably, as
reported in Figure 8, we found by RT-PCR analysis that
the mRNA encoding S1P1, S1P2, and S1P3 are specifically
expressed in primary cardiac muscle cells (Figure 8D),
whereas only S1P1 and S1P2 mRNA was detected in H9c2
cells (Figure 8E). Positive control corresponding to RT-
PCR performed using RNA obtained from C2C12 myo-
tubes that express all 3 S1P receptor subtypes is also re-
ported (Figure 8C). Due to the low level of expression in
primary cardiac muscle cells, the difference in S1P recep-
tor subtype expression between the 2 populations were
confirmed by real-time PCR. In Table 2, the Ct and Ct
for S1P1, S1P2, and S1P3 expression in primary cardiac
cells and H9c2 cells is reported. Temperature of melting
was equal to 79.91°C, 79.99°C, and 91.14°C for S1P1,
S1P2, and S1P3, respectively. Notably, real-time PCR
analysis indicated a similar expression level of all 3 recep-
tor subtypes in primary cardiac muscle cells and con-
firmed the lack of S1P3 expression in H9c2 cells. Further-
more, these findings indicate that the effect of exogenous
S1P may be mediated by either Gi- or Gs-coupled recep-
tors. The difference in the pattern of S1P receptor expres-
sion observed in primary cardiac muscle cells and H9c2
cells seems to not affect the cross-talk between S1P and
RLX in term of CTFG release. However, the role of S1P3
in primary cardiac muscle cells is worth investigating.
As reported in Nistri et al (15), RLX can promote the
maturation of mouse neonatal cardiomyocytes in vitro.
Based on this, we investigated whether S1P formation was
also involved in this action. As revealed by [3H]thymidine
incorporation (Table 3) and Western analysis of the key
protein involved in myocardial differentiation, Cx43
(Figure 9), the synthesis of the bioactive lipid was required
for RLX action. In particular, SphK activity inhibition
resulted in 45% reduction in [3H]thymidine incorpora-
tion and approximately 70% reduction in Cx43 expres-
sion in primary cardiac muscle cells, indicating that
SphK1/S1P axis is a crucial point in the biological action
of RLX on cardiac muscle cells.
Discussion
This study offers new evidence for a previously unidenti-
fied intracellular signaling pathway activated in cardiac
Figure 5. Effect of SphK, SMase, and S1P lyase inhibition and extracellular S1P addition on RLX-induced MMP-9 and MMP-2 activity in primary
cardiac muscle cells and H9c2 cells. A and B, Representative zymographs of latent (L)-MMP-9, active (A)-MMP-9, and MMP-2 activity from
conditioned media obtained from primary cardiac muscle cells (A) and H9c2 cardiomyoblasts (B) treated for 30 minutes with S1P (1M),
compound II (iSK, 5M), GW9846 (10M), or THI (6.5M) and then incubated in the absence or presence of RLX (50 ng/mL) over 24 hours.
Relative OD was determined by densitometry scanning and data as relative percentage to control (vehicle) arbitrarily normalized to 100 are
reported in the graphics. Data are mean  SEM of at least 3 independent experiments (Student’s t test; *, P  .05 vs untreated cells (vehicle);
§, P  .05 vs RLX). C and D, MMP-9 ELISA. Conditioned cell media obtained from primary cardiac muscle cells (C) and H9c2 cells (D) treated for 30
minutes with S1P (1M), compound II (iSK, 5M), GW9846 (10M), or THI (6.5M) and then incubated in absence or presence of RLX (50 ng/mL)
over 24 hours. Samples were analyzed and data reported as nanograms per milliliter as described in Materials and Methods. Data are mean  SEM
of at least 3 independent experiments (Student’s t test; *, P  .05 vs untreated cells (vehicle); §, P  .05 vs RLX).
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muscle cells by the cardiotropic hormone RLX, which
involves the generation of the bioactive lipid S1P.
Using in vitro cultures of immature primary cardiac
muscle cells from mouse neonatal hearts (15, 48) and rat
H9c2 cardiomyoblasts, we observed
that RLX, at concentrations similar
to those previously reported to elicit
specific responses in cardiac muscle
cells (15, 48, 49), induces SM me-
tabolism, SphK1 activation, and S1P
production. Of note, the RLX-in-
duced activation of SphK1 depends
on ERK1/2 phosphorylation. In fact,
pharmacological inhibition of ERK1/2,
but not p38 MAPK, prevented RLX-
mediated S1P formation.
The current findings indicate that
the RLX-induced activation of S1P
production is crucial for the capabil-
ity of this hormone to induce an
ECM-remodeling phenotype in car-
diac muscle cells. Indeed, inhibition
of the formation of SM metabolites
abolished the increase in MMPs and
decrease in TIMP-1 and CTGF ex-
pression induced by RLX in both
primary cardiac muscle cells and
H9c2 cardiomyoblasts. Of note,
stimulation of ECM turnover is re-
garded as a major effect of RLX,
well supported by much of the recent literature (50, 51),
acting through the upregulation of specific members of
the MMP family: MMP-1, -3, -9, and -13 (14, 46). This
action of RLX is mediated by its specific receptors, chiefly
Figure 6. Effect of SphK, SMase, and S1P lyase inhibition and extracellular S1P addition on RLX-
modulated TIMP-1 protein expression in H9c2 cells. Western blotting analysis of TIMP-1 protein
expression. Cell lysates (15–30 g) were obtained from H9c2 cells treated or not (vehicle) (A) for 30
minutes with the indicated agents (5M compound II [iSK], 10M GW9846, 6.5M THI, or 1M
S1P) (B) and then with RLX (50 ng/mL) for 24 hours as reported in Figure 5. Band intensity, reported
as relative percentage of the ratio between specific protein (TIMP-1)/-actin), normalized to vehicle or
to RLX value (set as 100), is shown in the graphics. A blot representative of at least 3 independent
experiments with similar results is shown. Data are mean  SEM (Student’s t test; §, P  .05 vs RLX).
Figure 7. Effect of SphK, SMase, and S1P lyase inhibition and extracellular S1P on CTGF expression in H9c2 cells. A and B, Western blot analysis
of CTGF protein expression was performed by using cell lysates (15–30 g) from untreated primary cardiac muscle cells (A) and H9c2
cardiomyoblasts (B) or treated for 30 minutes with indicated agents (5M compound II [iSK], 10M GW9846, 6.5M THI, or 1M S1P) and then
with vehicle or RLX (50 ng/mL) for 24 hours. Band intensity, reported as relative percentage of the ratio between CTGF/-actin, normalized to
control, set as 100, is shown in the graphic. A blot representative of at least 3 independent experiments with similar results is shown. Data are
mean  SEM (Student’s t test; *, P  .05 vs untreated cells (vehicle); §, P  .05 vs RLX).
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high-affinity RXFP1 (52). This acts as a Gs protein-cou-
pled receptor and signals through adenylate cyclase to
increase cAMP in different target cells (46). In particular,
RXFP1 activation results in cAMP elevation through
phosphatidylinositol-4,5-bisphosphate 3-kinase and cal-
cium - and phorbol ester-insensitive zeta isozyme of pro-
tein kinase C pathways, (53). The RLX/ERK1/2 axis is
also a classical downstream pathway of the cognate RLX
receptor, RXFP1 (46, 49), here demonstrated to be ex-
pressed in primary cardiac muscle cells and H9c2 car-
diomyoblasts. Therefore, the present study indicates that
SphK1 and S1P can be considered a novel ERK1/2-depen-
dent mechanism of the RLX/RXFP1
signaling pathway operating on car-
diac muscle cells.
SLs are present in most if not all
living organisms and cell types,
where they represent a class of
biomodulators of many cellular
functions (1–4). Among the bioac-
tive SLs derived by SM metabolism,
S1P has emerged in the last decade as
a crucial mediator of cardioprotec-
tion (3). Indeed, the level of S1P in
plasma is drastically reduced early
after MI, whereas the intracellular
content of other SLs such as cer-
amide, sphinganine, and Sph are un-
changed (54). Moreover, S1P medi-
ates the survival of cardiomyocytes
cultured under hypoxic conditions,
as well as pre- and postconditioning
in the heart subjected to ischemia/
reperfusion injury (3). Despite the
fact that both SphK1 and SphK2 iso-
forms catalyze the same reaction (3),
it appears that the SphK1 isoform,
predominantly localized in the cyto-
sol and plasma membrane, plays a
central role in cardioprotection (3). In line with this no-
tion, SphK1 transgenic mice have been shown to develop
progressive myocardial degeneration and fibrosis (55).
On the other hand, there are conflicting reports on the
role of SphK2 in ischemia-reperfusion injury (3), al-
though the isoform, which accounts for nuclear and car-
diac mitochondrial S1P generation, has also been shown
to be necessary for successful ischemic pre- and postcon-
ditioning and cardioprotection (56). In the experimental
conditions of the current study, SphK2 does not appear to
be involved in the RLX signaling.
Figure 8. Expression of S1P receptor subtype in H9c2, primary cardiac muscle cells, and C2C12
myotubes. A–E, Representative agarose gels of amplified cDNA fragments. Total RNA was
incubated with DNase and successively reverse transcribed. cDNAs were then amplified by PCR
using specific primers for TIMP-1 (A) and S1P1, S1P2, and S1P3 (B–E) as described in Materials and
Methods. TIMP-1 amplification was performed by using untreated () or RNA treated with
DNase (	) to eliminate DNA genomic contamination. B, Negative controls, consisting of no
template (water) in each PCR. C, Positive controls consisting of cDNA obtained from murine
C2C12 myotubes. D and E, cDNA amplification from reverse-transcribed RNA obtained from
primary cardiac muscle (D) and H9c2 cells (E).
Table 2. S1P Receptor Subtype Expression in H9c2
Cellsa
S1P1 S1P2 S1P3 GAPDH
Primary cardiac
muscle cells
Ct 17.44 17.97 17.28 13.26
Ct 4.18  0.5 4.71  0.6 4.02  0.7
H9c2 cells
Ct 21.89 20.00 14.52
Ct 7.37  0.8 5.48  0.7
a S1P receptor subtype expression was evaluated form total RNA of
primary cardiac muscle and H9c2 cells after reverse transcription and
real-time PCR amplification using specific primers as reported in
Materials and Methods. Ct values are reported as mean  SEM for
independent experiments performed in duplicate.
Table 3. Effect of SphK Inhibition on [3H]Thymidine





Vehicle 3453  288
RLX 50 ng/mL 2005  256b (42%)
RLX 	iSK 3056  510 (12%)
a Primary cardiac muscle cell proliferation was determined at 24 hours
from the addition of fresh culture medium (vehicle) or medium with
RLX or medium with SphK inhibitor (iSK) for 30 minutes before
hormone addition. [3H]Thymidine was added to the medium for the
last 2 hours. The -counts (dpm, disintegrations per minute) per well
are reported as mean  SEM for at least 3 independent experiments
performed in duplicate.
b Significance of differences (one-way ANOVA, n  3): P  .05. Note
no significant change was observed in the presence of iSK alone.







end/article/29/1/53/2556816 by guest on 08 N
ovem
ber 2020
Interestingly, in recent years, numerous studies have
established that bioactive lipids can modulate fibrogen-
esis in various organs, including the lung, skin, liver,
heart, and eye, by influencing both the onset and the
progression of the pathological accumulation of myofi-
broblasts and ECM (57). The rising interest in the ability
of SLs, in particular S1P, to reduce tissue fibrosis is based
on their ability to regulate key cellular processes involved
in tissue responses to injury (4) such as apoptosis, fibro-
blast migration and myofibroblast
differentiation, and TGF- signal-
ing. The present findings confirm
the ability of bioactive SLs to pro-
mote ECM remodeling by modulat-
ing the release of MMPs and add a
novel piece of knowledge demon-
strating that SLs are also required
for the profibrotic CTGF expression
elicited by RLX in cardiomyoblasts.
CTGF has been recently identified
as a key factor in heart remodeling
(58), because it regulates several cel-
lular processes, such as ECM depo-
sition, wound repair, and angiogen-
esis as well as cardiac cell migration,
differentiation, and survival (28).
Besides its major role in tissue fibro-
sis, CTGF has also been shown to
compete with Wnt family members
and to synergize with TGF-, sup-
porting a role for this cytokine as an
endogenous coordinator of multiple
signaling pathways (28, 29). A sin-
gle piece of evidence supports a role
of S1P in the downregulation of
CTGF at the mRNA level in mesangial cells (59). There-
fore, the current novel findings that RLX can decrease
CTGF expression through SL-mediated mechanisms ap-
pears particularly relevant, because they offer new per-
spectives for antifibrotic therapeutic approaches
Although we did not specifically investigate the action
of RLX on S1P receptor subtype-mediated signaling, the
current data indicate that primary cardiac muscle cells
and H9c2 cells expressed several S1P
receptor subtypes similarly to other
skeletal muscle cells, such as C2C12
myotubes (60). Extracellular S1P
was able to inhibit the effects of RLX
on the release of MMPs and potenti-
ate hormone action on CTGF expres-
sion likely through S1P1, S1P2, and/or
S1P3. In the heart, binding of S1P to
its specific receptors (61) activates
downstream signaling mechanisms
leading to modulation of cell sur-
vival and fibrosis (62, 63). More-
over, diminished circulating S1P lev-
els were observed in various human
diseases characterized by tissue fi-
brosis (64), and neutralization of
S1P with specific anti-S1P antibod-
Figure 9. Effect of SL metabolism inhibition and extracellular S1P addition on Cx43 expression
in primary cardiac muscle cells and H9c2 cells. A and B, Western blot analysis of Cx43 protein
expression. Cell lysates (10 g) from primary cardiac muscle cells were treated for 30 minutes
without (A) or with the indicated agents (5M compound II [iSK], 10M GW9846, 6.5M THI,
or 1M S1P) (B) and then with RLX (50 ng/mL) for 24 hours. Quantification of band intensity,
shown in the graphic, is reported as ratio between overall Cx43/-actin, and relative to control
normalized to 100. Data are mean  SEM (n  3, Student’s t test; *, P  .05 vs untreated cells
(vehicle); §, P  .05 vs RLX).
Figure 10. Scheme of the antifibrotic and procardiomyogenic RLX signaling involving SphK/S1P
axis in cardiac cells.
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ies significantly reduced TGF-stimulated collagen pro-
duction (62).
Because established tissue fibrosis is usually irrevers-
ible, preventative strategies capable of interrupting the
upstream biological processes that contribute to fibrogen-
esis can have a major therapeutic impact. In this view, a
possible cross-talk between the signaling pathways trig-
gered by activation of the specific RLX and S1P receptors
may be worthy of further investigation.
Our study also provides circumstantial evidence that
the SphK1/S1P axis can play an important role in the
differentiation of cardiac muscle precursors induced by
RLX. In fact, we observed that pharmacological inhibi-
tion of SphK counteracted the effect of RLX on Cx43
expression and cell cycle arrest, suggesting that an SphK1/
S1P-mediated signaling pathway is involved in the mod-
ulation of the cardiomyogenic program operated by RLX.
Conclusions
Taken together, the key findings of this study indicate
that RLX promotes an ECM-remodeling phenotype and
the maturation of cardiac muscle cells through the acti-
vation of endogenous S1P production and SM metabo-
lism (Figure 10). This notion can be relevant to heart
pathophysiology. In fact, RLX can be rightfully included
among the cardiotropic factors capable of inducing favor-
able myocardial remodeling in the diseased heart (23, 47).
In this view, human recombinant H2 RLX was found
effective in improving the clinical outcome and overall
survival of patients with acute heart failure (25, 26).
Thus, increasing the knowledge of the mechanisms in-
volved in increased ECM turnover, as well as in enhanced
self-renewal and in situ differentiation of resident myo-
cardial progenitor cells, is helpful to better understand the
intrinsic repair mechanisms of the failing heart (26) and
can provide a mechanistic background to RLX-based
therapeutic strategies in MI (65).
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